Oncology

Back to articles

Cisplatin: New Standard of Adjuvant Care for NSCLC

KEY POINT

In the quickly changing oncology world, cisplatin-based adjuvant chemotherapy is part of a new standard of care for patients with non–small-cell lung cancer (NSCLC). But it is not the only option, according to recently published articles, and therapy should be targeted based on patient and tumor characteristics.

SOURCES

The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer. N Engl J Med. 2004;350:351–60.

Blum RH. Adjuvant chemotherapy for lung cancer—a new standard of care [editorial]. N Engl J Med. 2004;350:404–5.

Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.